Genvec (Genvec) 3-Year Revenue Growth Rate : 0.00% (As of Mar. 2017)

View and export this data going back to 2000. Start your Free Trial

What is Genvec 3-Year Revenue Growth Rate?

Genvec's Revenue per Share for the three months ended in Mar. 2017 was $0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Genvec's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Genvec's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genvec's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genvec's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Genvec's 3-Year Revenue Growth Rate falls into.

Genvec 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Genvec (NAS:GNVC) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Genvec 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Genvec's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genvec (Genvec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (NAS:GNVC) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.genvec.com

Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.

Executives

Wayne T Hockmeyer	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Michael Richman	director	2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
Marc R Schneebaum	director	GENVEC, INC., 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Stefan Loren	director	3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Douglas J Swirsky	director, officer: President and CEO	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Willam N Kelley	director	MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Mmcap International Inc. Spc	10 percent owner	C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ecor1 Capital Fund Qualified, L.p.	other: See Explanation of Responses	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p.	other: See Explanation of Responses	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Zola P Horovitz	director	C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Cynthia Collins	director, officer: President & CEO	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Adel Mahmoud	director
Joshua Ruch	director	4 DUNE ROAD, EAST QUOGUE NY 11942

Genvec (Genvec) Headlines

From GuruFocus

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-07-2010

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-06-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus • 05-08-2009

GenVec Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 03-11-2011

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus • 08-07-2009